Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
February 16, 2017GutOpen Access

Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials

View Full Paper
Ask AI
Bookmark
Share

Authors

Julián Panés
Julián PanésHospital Clínic de Barcelona
William J. Sandborn
William J. SandbornSemmelweis University
Stefan Schreiber
Stefan SchreiberGoethe University Frankfurt

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Panés et al. (2017) studied this question.

synapsesocial.com/papers/69dbafa9387cf706986887f5https://doi.org/10.1136/gutjnl-2016-312735
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Changes in medical treatment and surgery rates in inflammatory bowel disease: a nationwide cohort study 1979–20112013 · 339 citations
  2. 2Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease2010 · 3,137 citations
  3. 3Anti-TNF Monoclonal Antibodies in Inflammatory Bowel Disease: Pharmacokinetics-Based Dosing Paradigms2012 · 508 citations
  4. 4Impact of New Treatments on Hospitalisation, Surgery, Infection, and Mortality in IBD: a Focus Paper by the Epidemiology Committee of ECCO2015 · 116 citations
  5. 5JAK inhibition using tofacitinib for inflammatory bowel disease treatment: a hub for multiple inflammatory cytokines2015 · 180 citations